^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    VTCN1 underexpression

    i
    Entrez ID:
    79679
    Related biomarkers:
    Expression
    Others
    Apply
    FPA150 in Patients With Advanced Solid Tumors (FPA150-001) (NCT03514121)
    Phase 1a/1b
    Five Prime Therapeutics, Inc.
    Completed
    Last update posted :
    01/11/2022
    Initiation :
    03/27/2018
    Primary completion :
    05/10/2021
    Completion :
    05/10/2021
    VTCN1
    |
    VTCN1 underexpression
    |
    Keytruda (pembrolizumab) • alsevalimab (FPA150)